contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vastra-hamnen-market-focus-xintela-licensing-deal-with-eqgen-biomedical

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Xintela operates in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes on the surface of cells, which enables the identification of stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.

Xintela

• Q&A with EQGen’s founders CMO Willem Scheele and CEO Grant Senner • License fee of MUSD 1 and shares in EQGen worth MUSD 3 • Our model suggests a fair value of SEK 1.43 per shareXintela and...

<div class="mfn-body"><p>• Q&amp;A with EQGen’s founders CMO Willem Scheele and CEO Grant Senner<br>• License fee of MUSD 1 and shares in EQGen worth MUSD 3<br>• Our model suggests a fair value of SEK 1.43 per share</p><p>Xintela and EQGen have entered a licensing and development agreement regarding EQSTEM, Xintela's stem cell product for the treatment of joint disease in horses, dogs and other animals. EQGen will have global rights to EQSTEM and other stem cell products for veterinary muscoloskeletal indications. In exchange, Xintela will receive a licensing fee of MUSD 1 and shares in EQGen corresponding to MUSD 3 and royalties on future sales. Västra Hamnen contacted EQGen's executive management for a comment on the collaboration.</p><p>We therefore maintain our risk-adjusted motivated value of SEK 1.30 per share. The full report is available <a rel="noopener" href="https://www.vhcorp.se/tjanster/marknadsfokus/xintela/xintela-licensing-deal-with-eqgen-biomedical">here</a>.</p></div><div class="mfn-footer mfn-about mfn-d368094d0583"><p><strong class="mfn-heading-1">About Market Focus</strong></p><hr><p>The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.<br><br>This is a press release from Västra Hamnen Corporate Finance AB.&nbsp;<br>Web:&nbsp;<a rel="noopener" href="https://vhcorp.se/">vhcorp.se</a><br>Twitter:&nbsp;@vhcorp_se&nbsp;(<a rel="noopener" href="https://twitter.com/vhcorp_se">https://x.com/vhcorp_se</a>)</p></div>